A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
A phase 1/2 trial of AS1986NS in prostate cancer, run by Antelope Surgical Solutions, Inc, now recruiting.
Overview
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS is a phase 1/2 interventional study registered as NCT06906471 by Antelope Surgical Solutions, Inc, with 10 participants planned, started 2026-07-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: AS1986NS.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares PSMA, Prostate cancer and the tag pipeline.
- AgentHRS-4357
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- AgentJNJ-87189401
Shares PSMA, Prostate cancer and the tag pipeline.